Novel brain-penetrant RNA therapeutic for treatment of amyotrophic lateral sclerosis

Active Project Grant Awarded Last action

Award ID
HT94252510181
Recipient
Awarding agency
Obligated
$1,979,313

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date 78% complete
Place of performance
Erie, CO 80516, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The U.S. Defense Health Agency awarded a $1,979,313 Project Grant to Sachi Bioworks, Inc., a small disadvantaged business in Erie, Colorado, to develop a novel brain-penetrant RNA therapeutic for the treatment of amyotrophic lateral sclerosis (ALS). This award is part of the agency's Military Medical Research and Development program (CFDA 12.420), which supports advanced biomedical research to transform healthcare for military service members, veterans, and the public. Sachi Bioworks specializes in innovative drug discovery platforms, leveraging its proprietary NanoligomerTM technology to create rapid, low-cost solutions for complex medical challenges. The funding will enable the company to further advance its research and development efforts focused on this brain-penetrant RNA therapy for ALS, a devastating neurodegenerative disease, with the goal of delivering an impactful medical solution.

Quick answers

Who received award HT94252510181?

HT94252510181 was awarded to Sachi Bioworks, Inc. by Defense Health Agency (Department of Defense) on April 1, 2025.

How much is award HT94252510181 worth?

$1,979,313 has been obligated on HT94252510181.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login